<DOC>
	<DOCNO>NCT00556712</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy , safety , pharmacokinetics Tarceva , compare placebo , follow platinum-based chemotherapy patient advance , recurrent , metastatic NSCLC disease progression unacceptable toxicity chemotherapy . Following 4 cycle platinum-based chemotherapy , eligible patient randomize receive either Tarceva 150mg po daily , placebo daily . The anticipated time study treatment disease progression ; target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Following Platinum-Based Chemotherapy Patients With Advanced , Recurrent , Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient &gt; =18 year age ; histologically document , locally advanced , recurrent metastatic NSCLC ; measurable disease ; disease progression 4 cycle platinumbased chemotherapy . unstable systemic disease ; malignancy last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>